Bortezomib will enhance the degree or outcome of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Greater flibanserin adverse consequences may well take place if coadministered with various weak CYP3A4 inhibitors. Display for hepatitis B virus in all most cancers patients starting up systemic therapy. Determine more details on https://simongzrka.livebloggs.com/32883293/considerations-to-know-about-cp-866087